Table 2.
Base case analysis and deterministic sensitivity analyses exploring variations in patient subgroups, cost, and treatment effects
| Parameter | Life-Years Gained | Incremental Cost | Incremental Benefit, QALY | ICER per QALY Gained |
|---|---|---|---|---|
| Base case | 11.82 | $48 635 | 4.77 | $10 186 |
| Grade II oligodendroglioma | 16.33 | $56 542 | 6.29 | $8985 |
| Grade II oligoastrocytoma | 12.30 | $63 475 | 5.00 | $12 695 |
| Grade II astrocytoma | 4.56 | $46 003 | 1.87 | $24 617 |
| IDH1 R132H mutation (+) | 14.57 | $32 539 | 6.51 | $5000 |
| Stable and progressing utilities 0.25 | 11.82 | $48 635 | 1.41 | $34 378 |
| Stable and progressing utilities 1.0 | 11.82 | $48 635 | 5.67 | $8581 |
| RT and PCV at 50% cost | 11.82 | $40 794 | 4.77 | $8544 |
| RT and PCV at double cost | 11.82 | $64 358 | 4.77 | $13 480 |
| RT and PCV at 400% cost | 11.82 | $95 721 | 4.77 | $20 048 |
| RT and PCV at 1000% cost | 11.82 | $189 894 | 4.77 | $39 772 |
Abbreviations: QALY, quality adjusted life years; IDH, isocitrate dehydrogenase; RT, radiotherapy; PCV, procarbazine, lomustine, vincristine; ICER, incremental cost-effectiveness ratio.